A Phase IIa clinical trial conducted with ALS patients confirmed that antiretroviral therapy (with efficacy against HERV-K HML-2) showed a trend toward delayed disease progression in patients with virological response.
← all excerpts
Viruses in neurodegenerative diseases: More than just suspects in crimes.
1
—
—